PRESS RELEASE TiGenix to present positive 52week Phase III results of Cx601 at World Congress of Gastroenterology at ACG 2017 meetingÂÂ Â Leuven BELGIUM October 5 2017 0700h CET TiGenix NV Euronext Brussels and NASDAQ TIG an advanced biopharmace...
↧